The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Abstract

Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at containing the outbreak of severe acute respiratory syndrome–coronavirus 2 (CoV-2). Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome–CoV and Middle East respiratory syndrome (MERS–CoV). RDV is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). Here, we co-expressed the MERS–CoV nonstructural proteins nsp5, nsp7, nsp8, and nsp12 (RdRp) in insect cells as a part a polyprotein to study the mechanism of inhibition of MERS–CoV RdRp by RDV. We initially demonstrated that nsp8 and nsp12 form an active complex. The triphosphate form of the inhibitor (RDV-TP) competes with its natural counterpart ATP. Of note, the selectivity value for RDV-TP obtained here with a steady-state approach suggests that it is more efficiently incorporated than ATP and two other nucleotide analogs. Once incorporated at position i , the inhibitor caused RNA synthesis arrest at position i + 3. Hence, the likely mechanism of action is delayed RNA chain termination. The additional three nucleotides may protect the inhibitor from excision by the viral 3′–5′ exonuclease activity. Together, these results help to explain the high potency of RDV against RNA viruses in cell-based assays.

Cited by papers we hold 24

• A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies · 2022
  No notice
• Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms · 2022
  No notice
• Antivirals for COVID-19: A critical review · 2021
  Not checked
• COVID-19 and cardiovascular system—a comprehensive review · 2021
  Not checked
• Putative Repurposing of Lamivudine, a Nucleoside/Nucleotide Analogue and Antiretroviral to Improve the Outcome of Cancer and COVID-19 Patients · 2021
  Not checked
• The Clinical Characteristics and Treatment Approaches of COVID-19:A Concise Review · 2021
  Not checked
• Impact of repurposed drugs on the symptomatic COVID-19 patients · 2021
  Not checked
• Mechanism of SARS-CoV-2 polymerase stalling by remdesivir · 2021
  No notice
• Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19 · 2021
  No notice
• An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19 · 2021
  No notice
• Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis · 2021
  No notice
• Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir · 2020
  No notice
• Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19 · 2020
  Not checked
• COVID-19: Recent updates on SARS-CoV-2 and Preventing its Community Transmission in India by 21 Days Lockdown · 2020
  Not checked
• Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines · 2020
  Not checked
• Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment · 2020
  No notice
• A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping · 2020
  No notice
• SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology · 2020
  No notice
• The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy · 2020
  Corrected
• How can nanotechnology help to combat COVID-19? Opportunities and urgent need · 2020
  No notice

and 4 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.